Biogen Idec (NASDAQ: BIIB) and Knopp Neurosciences announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's...
In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp Neurosciences Inc. ("Knopp") described further encouraging trends observed in a previously reported Phase 2 study of KNS-760704 (dexpramipexole) in ALS. Knopp reported that post hoc analyses...